Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2007-04-17
2007-04-17
Bernhardt, Emily (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C544S400000, C540S575000, C514S218000
Reexamination Certificate
active
10745224
ABSTRACT:
Disclosed are novel heterocyclic compounds having the structurewhich are useful for the treatment of various disease states, m particular cardiovascular diseases such as atrial and ventricular arrhythmias, intermittent claudication, Prinzmetal's (variant) angina, stable and unstable angina, exercise induced angina, congestive heart disease, and myocardial infarction. The compounds are also useful in the treatment of diabetes.
REFERENCES:
patent: 4558129 (1985-12-01), Kluge et al.
patent: 4567264 (1986-01-01), Kluge et al.
patent: 4766125 (1988-08-01), Van Daele et al.
patent: 5472707 (1995-12-01), Samuels et al.
patent: 5506229 (1996-04-01), Dow et al.
patent: 5906988 (1999-05-01), Dow
patent: 6451798 (2002-09-01), Varkhedkar et al.
patent: 6552023 (2003-04-01), Zablocki et al.
patent: 6573264 (2003-06-01), Zablocki et al.
patent: 6638970 (2003-10-01), Elzein et al.
patent: 6677336 (2004-01-01), Zablocki et al.
patent: 6677343 (2004-01-01), Blackburn et al.
patent: 2003/0181352 (2003-09-01), Ibrahim et al.
patent: 2005/0153981 (2005-07-01), Li et al.
patent: 0 407 780 (1991-01-01), None
patent: 483 932 (1992-06-01), None
patent: 03 141258 (1991-06-01), None
patent: WO 01/62744 (2001-08-01), None
patent: WO 01/62749 (2001-08-01), None
U.S. Appl. No. 10/729,499, filed Dec. 5, 2003, Elzein et al.
McCormick, et al. “Ranolazine: A Novel Metabolic Modulator for the Treatment of Angina”, Gen Pharmac., vol. 30, No. 5, pp. 639-645, (1998).
Suzuki T et al: “Structure-activity relationship of newly synthesized quinoline derivatives for reversal of multidrug resistance in cancer.”, Journal of Chemistry, vol. 40, No. 13, 1997, pp. 2047-2052, XP000924067, the whole document, particularly p. 2049, table 2, compound 5.
Zacharowski K et al: “Ranolazine, a partial fatty acid oxidation inhibitor, reduces myocardial infarct size and cardiac troponin T release in the rat.” European Journal of Pharmacology, vol. 418, No. 1-2, Apr. 20, 2001, pp. 105-110, XP002215620, the whole document.
Lopaschuk G D: “Treating ischemic heart disease by pharmacologically improving cardiac energy metabolism”, The American Journal of Cardiology, vol. 82, No. 5A, Sep. 3, 1997, pp. 14K-17K, XP002215621, the whole document.
Li, Jianqi et al.: “Preparation Of Aroylalkylpiperazine Derivatives As Neuroprotectants For Cerebral Ischemia” Database Accession No. 2003:759269, XP002282398, abstract.
Palle Venkata
Zablocki Jeff
Bernhardt Emily
CV Therapeutics Inc.
Hartrum J. Elin
Lewis Brian
LandOfFree
Substituted heterocyclic compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Substituted heterocyclic compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted heterocyclic compounds will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3745745